Modality
ADC
MOA
PD-L1i
Target
SOS1
Pathway
Notch
ALLBCC
Development Pipeline
Preclinical
~Jul 2017
→ ~Oct 2018
Phase 1
~Jan 2019
→ ~Apr 2020
Phase 2
~Jul 2020
→ ~Oct 2021
Phase 3
~Jan 2022
→ ~Apr 2023
NDA/BLA
~Jul 2023
→ ~Oct 2024
Approved
Jan 2025
→ Jan 2031
ApprovedCurrent
NCT04232406
1,063 pts·ALL
2025-01→2031-01·Active
1,063 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2031-01-214.8y awayPh3 Readout· ALL
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031
Approved
Active
Catalysts
Ph3 Readout
2031-01-21 · 4.8y away
ALL
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04232406 | Approved | ALL | Active | 1063 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Miriglumide | Alnylam | Phase 3 | CD3 |